Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Survey of current practices from an international task force for gynecological stereotactic ablative radiotherapy.

Leung E, Gladwish A, Sahgal A, Lo SS, Kunos CA, Lanciano RM, Mantz CA, Guckenberger M, Zagar TM, Mayr NA, Chang AR, Jorcano S, Biswas T, Pontoriero A, Albuquerque KV.

Radiat Oncol. 2020 Jan 30;15(1):24. doi: 10.1186/s13014-020-1469-8.

2.

Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal Cancers.

Kunos CA, Andrews SJ, Moore KN, Chon HS, Ivy SP.

Front Oncol. 2019 Oct 15;9:1067. doi: 10.3389/fonc.2019.01067. eCollection 2019.

3.

Clinical Outcome Assessments Toolbox for Radiopharmaceuticals.

Kunos CA, Capala J, Dicker AP, Movsas B, Ivy SP, Minasian LM.

Front Oncol. 2019 Oct 10;9:1028. doi: 10.3389/fonc.2019.01028. eCollection 2019.

4.

Single-Arm Phase II Trials of Combination Therapies: A Review of the CTEP Experience 2008-2017.

Foster JC, Freidlin B, Kunos CA, Korn EL.

J Natl Cancer Inst. 2020 Feb 1;112(2):128-135. doi: 10.1093/jnci/djz193.

5.

Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.

Ivy SP, Kunos CA, Arnaldez FI, Kohn EC.

Expert Opin Investig Drugs. 2019 Sep;28(9):771-785. doi: 10.1080/13543784.2019.1657403. Epub 2019 Aug 30. Review.

PMID:
31449760
6.

Leveraging National Cancer Institute Programmatic Collaboration for Single Radiopharmaceutical Drug Master Files.

Kunos CA, Capala J, Ivy SP.

Front Oncol. 2019 Jun 28;9:573. doi: 10.3389/fonc.2019.00573. eCollection 2019.

7.

Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer.

Kunos CA, Capala J, Kohn EC, Ivy SP.

Front Oncol. 2019 Jun 26;9:560. doi: 10.3389/fonc.2019.00560. eCollection 2019.

8.
9.

Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers.

Kunos CA, Capala J, Finnigan S, Smith GL, Ivy SP.

Front Oncol. 2019 Mar 26;9:180. doi: 10.3389/fonc.2019.00180. eCollection 2019.

10.

Radiopharmaceuticals for Relapsed or Refractory Leukemias.

Kunos CA, Capala J, Ivy SP.

Front Oncol. 2019 Feb 25;9:97. doi: 10.3389/fonc.2019.00097. eCollection 2019.

11.

National Cancer Institute Programmatic Collaboration for Investigational Radiopharmaceuticals.

Kunos CA, Capala J.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:488-494. doi: 10.1200/EDBK_200199. Review.

12.

A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study.

Boardman CH, Brady WE, Dizon DS, Kunos CA, Moore KN, Zanotti KM, Matthews C, Cosin JA, Aghajanian C, Fracasso PM.

Gynecol Oncol. 2018 Nov;151(2):202-207. doi: 10.1016/j.ygyno.2018.08.006. Epub 2018 Aug 31.

13.

Triapine Radiochemotherapy in Advanced Stage Cervical Cancer.

Kunos CA, Ivy SP.

Front Oncol. 2018 May 7;8:149. doi: 10.3389/fonc.2018.00149. eCollection 2018.

14.

Leveraging National Cancer Institute Programmatic Collaboration for Uterine Cervix Cancer Patient Accrual in Puerto Rico.

Kunos CA, Massett HA, Galassi A, Walker JL, Good MJ, Díaz LB, McCaskill-Stevens W.

Front Oncol. 2018 Apr 10;8:102. doi: 10.3389/fonc.2018.00102. eCollection 2018.

15.

Editorial: New Approaches to Radiation-Therapeutic Agent Cancer Care for Women.

Kunos CA, Kohn EC.

Front Oncol. 2017 Nov 16;7:276. doi: 10.3389/fonc.2017.00276. eCollection 2017. No abstract available.

16.

Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop.

Marciscano AE, Walker JM, McGee HM, Kim MM, Kunos CA, Monjazeb AM, Shiao SL, Tran PT, Ahmed MM.

J Immunother Cancer. 2018 Jan 29;6(1):6. doi: 10.1186/s40425-018-0317-y.

17.

Current and Future Initiatives for Radiation Oncology at the National Cancer Institute in the Era of Precision Medicine.

Kunos CA, Coleman CN.

Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):18-25. doi: 10.1016/j.ijrobp.2017.02.225. Epub 2018 Jan 8. No abstract available.

PMID:
29325810
18.

Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations.

Kunos CA, Galanis E, Buchsbaum J, Shi Q, Strauss LC, Coleman CN, Ahmed MM.

J Neurooncol. 2017 Sep;134(3):551-557. doi: 10.1007/s11060-017-2458-0. Epub 2017 May 30. Review.

19.

Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers.

Kunos CA, Chu E, Makower D, Kaubisch A, Sznol M, Ivy SP.

Front Oncol. 2017 Apr 4;7:62. doi: 10.3389/fonc.2017.00062. eCollection 2017.

20.
21.

Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies.

Kunos CA, Chu E, Beumer JH, Sznol M, Ivy SP.

Cancer Chemother Pharmacol. 2017 Jan;79(1):201-207. doi: 10.1007/s00280-016-3200-x. Epub 2016 Nov 22.

22.

Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration.

Takebe N, Ahmed MM, Vikram B, Bernhard EJ, Zwiebel J, Norman Coleman C, Kunos CA.

Semin Radiat Oncol. 2016 Oct;26(4):271-80. doi: 10.1016/j.semradonc.2016.06.005. Epub 2016 Jun 15. Review.

PMID:
27619249
23.

Impact of nurse navigation on timeliness of diagnostic medical services in patients with newly diagnosed lung cancer.

Kunos CA, Olszewski S, Espinal E.

J Community Support Oncol. 2015 Jun;13(6):219-24. doi: 10.12788/jcso.0141.

PMID:
26270521
24.

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy.

Kunos CA, Fabien JM, Shanahan JP, Collen C, Gevaert T, Poels K, Van den Begin R, Engels B, De Ridder M.

J Vis Exp. 2015 Jun 7;(100):e52875. doi: 10.3791/52875.

25.

Phase I Trial of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Ablative Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer.

Kunos CA, Sherertz TM, Mislmani M, Ellis RJ, Lo SS, Waggoner SE, Zanotti KM, Herrmann K, Debernardo RL.

Front Oncol. 2015 Jun 5;5:126. doi: 10.3389/fonc.2015.00126. eCollection 2015.

26.

Determination of triapine, a ribonucleotide reductase inhibitor, in human plasma by liquid chromatography tandem mass spectrometry.

Feng Y, Kunos CA, Xu Y.

Biomed Chromatogr. 2015 Sep;29(9):1380-7. doi: 10.1002/bmc.3434. Epub 2015 Feb 10.

PMID:
25677991
27.

Two-step procedure for evaluating experimentally induced DNA damage: Texas Red and Comet assays.

Ferris GJ, Shunkwiler LB, Kunos CA.

Methods Mol Biol. 2015;1249:183-91. doi: 10.1007/978-1-4939-2013-6_13.

PMID:
25348306
28.

Comparison and consensus guidelines for delineation of clinical target volume for CT- and MR-based brachytherapy in locally advanced cervical cancer.

Viswanathan AN, Erickson B, Gaffney DK, Beriwal S, Bhatia SK, Lee Burnett O 3rd, D'Souza DP, Patil N, Haddock MG, Jhingran A, Jones EL, Kunos CA, Lee LJ, Lin LL, Mayr NA, Petersen I, Petric P, Portelance L, Small W Jr, Strauss JB, Townamchai K, Wolfson AH, Yashar CM, Bosch W.

Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):320-8. doi: 10.1016/j.ijrobp.2014.06.005.

29.

Hydration during breast radiotherapy may lower skin toxicity.

Kunos CA, Abdallah RR, Lyons JA.

Breast J. 2014 Nov-Dec;20(6):679-81. doi: 10.1111/tbj.12348. Epub 2014 Sep 23. No abstract available.

PMID:
25252223
30.

Long-Term Disease Control with Triapine-Based Radiochemotherapy for Patients with Stage IB2-IIIB Cervical Cancer.

Kunos CA, Sherertz TM.

Front Oncol. 2014 Jul 24;4:184. doi: 10.3389/fonc.2014.00184. eCollection 2014.

32.

Acute gastrointestinal toxicity after robotic stereotactic ablative radiotherapy for treatment of metastatic gynecological malignancies.

Mislmani M, Frasure H, Suppiah S, Fabien J, Lo SS, Debernardo R, Kunos CA.

Future Oncol. 2014 Feb;10(2):241-8. doi: 10.2217/fon.13.215.

PMID:
24490610
33.
34.

Cabazitaxel-induced stabilization of microtubules enhances radiosensitivity in ovarian cancer cells.

Kunos CA, Stefan T, Jacobberger JW.

Front Oncol. 2013 Sep 18;3:226. doi: 10.3389/fonc.2013.00226. eCollection 2013.

35.

Role of stereotactic radiosurgery in gynecologic cancer.

Kunos CA, Spelic M.

Curr Opin Oncol. 2013 Sep;25(5):532-8. doi: 10.1097/CCO.0b013e328363e0ad. Review.

PMID:
23942297
36.

Radiation quality, like art, consists in drawing the line somewhere.

Kunos CA, Petersen IA.

Front Oncol. 2013 Jul 17;3:163. doi: 10.3389/fonc.2013.00163. eCollection 2013.

37.

Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers.

Kunos CA, Radivoyevitch T, Waggoner S, Debernardo R, Zanotti K, Resnick K, Fusco N, Adams R, Redline R, Faulhaber P, Dowlati A.

Gynecol Oncol. 2013 Jul;130(1):75-80. doi: 10.1016/j.ygyno.2013.04.019. Epub 2013 Apr 18.

38.

Emerging role of stereotactic body radiotherapy in the treatment of pancreatic cancer.

Berber B, Sanabria JR, Braun K, Yao M, Ellis RJ, Kunos CA, Sohn J, Machtay M, Teh BS, Huang Z, Mayr NA, Lo SS.

Expert Rev Anticancer Ther. 2013 Apr;13(4):481-7. doi: 10.1586/era.13.19. Review.

PMID:
23560842
39.

Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis.

Kunos CA, Winter K, Dicker AP, Small W Jr, Abdul-Karim FW, Dawson D, Jhingran A, Valicenti R, Weidhaas JB, Gaffney DK.

Int J Gynecol Cancer. 2013 May;23(4):615-21. doi: 10.1097/IGC.0b013e31828b4eb5.

40.

Phase II Clinical Trial of Robotic Stereotactic Body Radiosurgery for Metastatic Gynecologic Malignancies.

Kunos CA, Brindle J, Waggoner S, Zanotti K, Resnick K, Fusco N, Adams R, Debernardo R.

Front Oncol. 2012 Dec 5;2:181. doi: 10.3389/fonc.2012.00181. eCollection 2012.

41.

dNTP Supply Gene Expression Patterns after P53 Loss.

Radivoyevitch T, Saunthararajah Y, Pink J, Ferris G, Lent I, Jackson M, Junk D, Kunos CA.

Cancers (Basel). 2012 Nov 20;4(4):1212-24. doi: 10.3390/cancers4041212.

42.

Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers.

Kunos CA, Radivoyevitch T, Kresak A, Dawson D, Jacobberger J, Yang B, Abdul-Karim FW.

Int J Gynecol Cancer. 2012 Nov;22(9):1463-9. doi: 10.1097/IGC.0b013e318270577f.

43.

Therapeutic Mechanisms of Treatment in Cervical and Vaginal Cancer.

Kunos CA.

Oncol Hematol Rev. 2012 Spring;8(1):55-60.

44.

Hematological toxicity after robotic stereotactic body radiosurgery for treatment of metastatic gynecologic malignancies.

Kunos CA, Debernardo R, Radivoyevitch T, Fabien J, Dobbins DC, Zhang Y, Brindle J.

Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):e35-41. doi: 10.1016/j.ijrobp.2012.02.027. Epub 2012 Apr 28.

PMID:
22543208
45.

Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone-induced methemoglobinemia.

Kunos CA, Radivoyevitch T, Ingalls ST, Hoppel CL.

Future Oncol. 2012 Feb;8(2):145-50. doi: 10.2217/fon.11.147. Review.

46.

On model ensemble analyses of nonmonotonic data.

Radivoyevitch T, Kunos CA.

Nucleosides Nucleotides Nucleic Acids. 2012;31(2):147-56. doi: 10.1080/15257770.2011.644370.

47.

Robotic surgery in gynecologic oncology.

Debernardo R, Starks D, Barker N, Armstrong A, Kunos CA.

Obstet Gynecol Int. 2011;2011:139867. doi: 10.1155/2011/139867. Epub 2011 Nov 16.

48.

Helical tomotherapy versus conventional radiation to deliver abdominopelvic radiation.

Choe J, Kulasekere R, Oddo D, Anthony S, Shin T, Murray M, Kunos CA.

Technol Cancer Res Treat. 2012 Feb;11(1):49-56.

PMID:
22181331
49.

18FDG-PET/CT Definition of Clinical Target Volume for Robotic Stereotactic Body Radiosurgery Treatment of Metastatic Gynecologic Malignancies.

Kunos CA, Debernardo R, Fabien J, Dobbins DC, Zhang Y, Brindle J, Faulhaber PF.

J Nucl Med Radiat Ther. 2011 Dec 12;Suppl 4(1). pii: 3117.

50.

Supplemental Content

Loading ...
Support Center